1. Access To Medicine Foundation. (2021). Strategic direction 2017–2021, access to medicine foundation (Hrsg.). https://accesstomedicinefoundation.org/medialibrary/resources/5bf40d5c8ebbe_Access%20to%20Medicine%20Foundation_Strategic%20Direction_2017-2021.pdf. Zugegriffen: 24. Apr. 2022.
2. Adigwe, O. P., & Oturu, D. (2022). The role of patent waivers and compulsory licensing in facilitating access to COVID-19 vaccines: Findings from a survey among healthcare practitioners in Nigeria. PLOS Global Public Health, 2(7), e0000683.
3. Banerji, A., & Suri, F. K. (2017). Patents, R&D expenditure, regulatory filings and exports in Indian pharmaceutical industry. Journal of Intellectual Property Rights, 22(3), 136–145.
4. Beck, E. J., Mandalia, S., Dongmo Nguimfack, B., Pinheiro, E., ‘t Hoen, E., Boulet, P., Stover, J., Gupta, A., Juneja, S., Habiyambere, V., Ghys, P., & Nunez, C. (2019). Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries? Global Health Action, 12(1), 1–13.
5. Bican, P. M., & Truong, Q. N. (2014a). Bayer in India: Intellectual Property Expropriation. Case Study. ISB-IVEY Publications. S. 1–16. https://www.iveypublishing.ca/s/product/bayer-in-india-intellectual-property-expropriation/01t5c00000CwjmHAAR. Zugegriffen: 2. Apr. 2023.